摘要
目的探讨在二甲双胍治疗的基础上,联合司美格鲁肽对超重或肥胖2型糖尿病患者的影响。方法此次研究在50例样本中进行,该50例样本为单中心选例,均选自天津市西青区大寺镇社区卫生服务中心在2022年7月-2023年5月之间收治的超重或肥胖2型糖尿病患者,研究对象入组后即对其进行组别的分配,按照随机数字表法分为对照组(接受二甲双胍、胰岛素治疗)与观察组(接受二甲双胍、胰岛素+司美格鲁肽治疗),两组例数相等,均为25例,均治疗3个月。比较两组各项临床指标。结果二者总有效率比较,结果说明观察组更高(92.00%vs 68.00%),且组间对比数据差异明显(P<0.05)。治疗3个月后与治疗前比:两组血清FPG、2h BG、HOMA-IR、BMI水平均下降,且与对照组相比,观察组处于更低水平;两组HOMA-β水平均升高,且与对照组相比,观察组处于更高水平;治疗3个月后,观察组TIR短于对照组,组间差异具有显著性(P<0.05)。与对照组比较,观察组治疗期间的不良反应总发生率略高,但组间差异不明显(P>0.05)。结论超重或肥胖2型糖尿病患者采用司美格鲁肽联合二甲双胍治疗,能够控制血糖代谢,改善胰岛功能,降低体质量,且疗效显著,不增加不良反应。
Objective To investigate the effect of combined simegallutide on overweight or obese type 2 diabetes patients based on metformin therapy.Methods The study in 50 samples,the 50 samples for single center,choose the self hospital between July 2022 to May 2023,overweight or obese type 2 diabetes patients,subjects after the group allocation,divided into control group(metformin,insulin treatment)and observation group(metformin,insulin+lutide treatment),with equal number,are 25 cases.All patients were treated for 3 months.Various clinical indicators were compared between the two groups.Results The comparison of the total response rate indicates that the observation group was higher(92.00%vs 68.00%),and the comparison data between the groups were significantly different(P<0.05).After 3 months of treatment and the pre-treatment ratio:serum FPG,2h BG,HOMA-IR,BMI decreased in both groups,and the observation was lower than that of the control group;HOMA-βwas increased in the two groups,compared with the control group;the observation group was higher;and after 3 months of treatment,the TIR of the observation group was shorter than that of the control group,and the difference between groups was significant in the statistical software(P<0.05).Compared with the control group,the overall incidence of adverse reactions during the treatment was slightly higher in the observation group,but the difference between the groups was not significant(P>0.05).Conclusion In overweight or obese patients with type 2 diabetes,selmeaglutide and metformin can control blood glucose metabolism,improve islet function and reduce body mass without increasing adverse effects.
作者
刘晓娟
丁雪梅
单秋妹
温建忠
李越琪
Liu Xiaojuan;Ding Xuemei;Shan Qiumei;Wen Jianzhong;Li Yueqi(Dasi Town Community Health Service Center,Xiqing District,Tianjin 300000,China;Wuqing District People's Hospital,Tianjin 301700,China)
出处
《首都食品与医药》
2024年第10期62-64,共3页
Capital Food Medicine
关键词
2型糖尿病
司美格鲁肽
胰岛功能
血糖代谢
type 2 diabetes
simegallutide
islet function
blood glucose metabolism
